,i #aagth ,,congress #ast ,session ,h4 ,r4 #dgaa ,,in ,,the ,,house ,,of ,,representatives ,july #bg1 #bjba,mr4 ,joyce of ,pennsylvania 7for himself and ,mr4 ,banks7 introduced the following bill2 which was referred to the ,committee on ,ways and ,means1 and in addition to the ,committee on ,rules1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend the ,bipartisan ,congressional ,trade ,priorities and ,accountability ,act of #bjae to include principal negotiating objectives of the ,united ,states relating to trade in pharmaceutical products1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,international ,pharmaceutical ,supply ,chain ,security ,agreement ,act of #bjba4 #b4 ,principal negotiating objectives of the ,united ,states relating to trade in covered pharmaceutical products ,section #ajb7;b7 of the ,bipartisan ,congressional ,trade ,priorities and ,accountability ,act of #bjae 7#ai ,u4,s4,c4 #dbja7;b77 is amended by adding at the end the following3 7#bc7 ,trade in covered pharmaceutical products 7,a7 ,in general ,with respect to an agreement relating to trade in covered pharmaceutical products that is proposed to be entered into with the ,united ,states and to which section #ajc7;b7 will apply1 the principal negotiating objectives of the ,united ,states are the following3 7i7 ,to ensure that a party to the agreement adopts and maintains measures to eliminate the imposition or reimposition of tariffs on imports of such products1 particularly in the event of a declared emergency4 7ii7 ,to ensure that a party to the agreement-- 7,i7 will reduce or eliminate regulatory and other technical barriers in the pharmaceutical sector2 7,,ii7 will promote expedited approval of facilities for the production of such products being built by business enterprises that operate one or more such facilities in the territory of the party2 7,,iii7 will promote the use of good regulatory practices and streamlined regulatory review and approval processes for the production of such products in the territory of the party2 7,,iv7 will eliminate duplicated actions and other barriers to reduce the time for approvals of both facilities and such products2 and 7,v7 will expand transparency and cooperation with other parties and their manufacturers1 working collaboratively1 to ensure regulatory processes are streamlined and harmonized among other parties to the maximum extent possible4 7iii7 ,to prohibit export restraints against parties to the agreement1 particularly in the event of a declared emergency4 7iv7 ,with respect to use of subsidies-- 7,i7 to encourage the coordinated provision of those types of subsidies that are classified under ,world ,trade ,organization rules as non-prohibited1 such as subsidies that are not contingent on exports or import-substitution1 to incentivize manufacturing of such products1 including the provision of grants1 loans1 tax incentives1 and guaranteed price and volume contracts2 7,,ii7 to explicitly permit1 among parties to the agreement1 the use of production subsidies to build pharmaceutical manufacturing capacity2 7,,iii7 to affirm that subsidies provided by parties are not intended to be used primarily for export or to distort trade2 7,,iv7 to affirm parties' commitments under the ,antidumping ,agreement and the ,agreement on ,subsidies and ,countervailing ,measures1 including the recognition that dumping1 by which products of one country are introduced into the commerce of another country at less than the normal value of the products1 is to be condemned if it causes or threatens material injury to an established industry in the territory of a contracting party or materially retards the establishment of a domestic industry2 and 7,v7 to encourage notification and consultation among parties as they are considering pharmaceutical manufacturing subsidies to increase coordination and avoid creating conditions such as oversupply or market inefficiencies among the parties4 7v7 ,with respect to government procurement-- 7,i7 to provide reciprocal access to government procurements for such products in parties to the agreement2 7,,ii7 to increase coordination between participant countries and facilitate the involvement of participant countries' companies in bids to supply such products2 and 7,,iii7 to ensure that any participant in the agreement that is not already so designated1 becomes designated for purposes of section #cja of the ,trade ,agreements ,act of #aigi 7#ai ,u4,s4,c4 #beaa74 7vi7 ,with respect to trade in services-- 7,i7 to obtain fair1 open1 and transparent access to supply chain services in the markets of parties to the agreement1 such as distribution1 logistics1 and transportation services2 7,,ii7 to ensure any restrictions or regulatory requirements maintained on such services are adopted and maintained in a transparent and efficient manner2 and 7,,iii7 to require parties to establish an internal process for identifying restrictions or regulatory requirements that could be waived in the event of a declared emergency4 7vii7 ,with respect to transparency and trade facilitation-- 7,i7 to obtain commitments among parties to the agreement to develop mechanisms for sharing information on pharmaceutical supply chain constraints and coordinate approaches with parties to minimize risks that could lead to supply chain failures2 and 7,,ii7 to the extent they have not done so yet1 to obtain commitments from parties that they will fully implement the obligations under the ,world ,trade ,organization's ,agreement on ,trade ,facilitation prior to the date the agreement enters into force4 7viii7 ,with respect to enforcement-- 7,i7 to ensure that benefits under the agreement can only be obtained by parties that are fully meeting their obligations under the agreement2 7,,ii7 to ensure that parties will not bring a dispute under another agreement for actions that are consistent with the agreement2 and 7,,iii7 to provide a dispute settlement mechanism comparable to the dispute settlement provisions of the ,agreement between the ,united ,states of ,america1 the ,united ,mexican ,states1 and ,canada4 7ix7 ,to minimize the ability of parties to the agreement to undermine the effectiveness of the agreement by abusing exceptions in the agreement by including additional procedural requirements1 such as notification of intent to rely on an exception at the time an inconsistent action is taken1 and limiting the duration that participants may rely on an exception4 7,b7 ,definitions ,in this paragraph3 7i7 ,active pharmaceutical ingredient ,the term active pharmaceutical ingredient-- 7,i7 means any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis1 cure1 mitigation1 treatment1 or prevention of a disease1 or to affect the structure or any function of the body of a human or animal2 and 7,,ii7 does not include-- 7aa7 intermediates used in the synthesis of a drug product2 or 7bb7 components that may undergo chemical change in the manufacture of a drug product and be present in a drug product in a modified form that is intended to furnish such activity or effect4 7ii7 ,agreement on ,subsidies and ,countervailing ,measures ,the term ,agreement on ,subsidies and ,countervailing ,measures means the agreement referred to in section #aja7;d77#ab7 of the ,uruguay ,round ,agreements ,act 7#ai ,u4,s4,c4 #ceaa7;d77#ab774 7iii7 ,antidumping ,agreement ,the term ,antidumping ,agreement means the ,agreement on ,implementation of ,article ,,vi of the ,general ,agreement on ,tariffs and ,trade #aiid referred to in section #aja7;d77#g7 of the ,uruguay ,round ,agreements ,act 7#ai ,u4,s4,c4 #ceaa7;d77#g774 7iv7 ,biological product ,the term biological product has the meaning given to such term in section #cea7;i7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i774 7v7 ,covered pharmaceutical product ,the term covered pharmaceutical product means-- 7,i7 a drug 7including a biological product72 or 7,,ii7 an active pharmaceutical ingredient4 4 #c4 ,reauthorization of trade agreements authority ,section #ajc of the ,bipartisan ,congressional ,trade ,priorities and ,accountability ,act of #bjae 7#ai ,u4,s4,c4 #dbjb7 is amended-- 7#a7 in subsection 7a7-- 7,a7 by striking ,july #a1 #bjah each place it appears and inserting ,july #a1 #bjbc2 and 7,b7 by striking ,july #a1 #bjba each place it appears and inserting ,july #a1 #bjbf2 7#b7 in subsection 7b7-- 7,a7 by striking ,july #a1 #bjah each place it appears and inserting ,july #a1 #bjbc2 and 7,b7 by striking ,july #a1 #bjba each place it appears and inserting ,july #a1 #bjbf2 and 7#c7 in subsection 7c7-- 7,a7 by striking ,july #a1 #bjah each place it appears and inserting ,july #a1 #bjbc2 7,b7 by striking ,june #cj1 #bjah and inserting ,june #cj1 #bjbc2 7,c7 in paragraph 7#a77;,b71 by striking ,july #a1 #bjba and inserting ,july #a1 #bjbf2 7,d7 in paragraph 7#b71 by striking ,april #a1 #bjah and inserting ,april #a1 #bjbc2 and 7,e7 in paragraph 7#c71 by striking ,june #a1 #bjah and inserting ,june #a1 #bjbc4